Payment overview · 2025
General Payments
$315.98
15 reported records · 9 companies
Healthcare provider profile · identity verified
Michael J Magidow, MD, PHD
Allopathic & Osteopathic Physicians|Family Medicine · BUFFALO GROVE, IL · NPI 1649479296
Verified facts
What the public records show
CMS Open Payments records show Michael J Magidow, MD, PHD received $315.98 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.00 | 28.8% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $36.90 | 11.7% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $33.23 | 10.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.10 | 9.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.10 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.04 | 8.6% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $25.14 | 8.0% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $24.82 | 7.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.65 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $315.98 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $68.64 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $68.64 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 59 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 247 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 58 |
| Metformin Hcl | Metformin Hcl | 221 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 219 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 38 |
| Losartan Potassium | Losartan Potassium | 164 | 36 |
| Lisinopril | Lisinopril | 143 | 39 |
| Chlorthalidone | Chlorthalidone | 135 | 31 |
| Omeprazole | Omeprazole | 127 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 29 |
| Januvia | Sitagliptin Phosphate | 102 | 15 |
| Eliquis | Apixaban | 97 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 24 |
| Farxiga | Dapagliflozin Propanediol | 92 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 22 |
| Labetalol Hcl | Labetalol Hcl | 91 | 22 |
| Bumetanide | Bumetanide | 88 | 13 |
| Ursodiol | Ursodiol | 88 | 19 |
| Carvedilol | Carvedilol | 85 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 16 |
| Trazodone Hcl | Trazodone Hcl | 82 | 23 |
| Vascepa | Icosapent Ethyl | 81 | 13 |
| Montelukast Sodium | Montelukast Sodium | 73 | 14 |
| Gabapentin | Gabapentin | 72 | 18 |
| Valsartan | Valsartan | 63 | 11 |
| Creon | Lipase/Protease/Amylase | 59 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 21 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Irbesartan | Irbesartan | 55 | suppressed |
| Spironolactone | Spironolactone | 53 | 13 |
| Linzess | Linaclotide | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Famotidine | Famotidine | 44 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Furosemide | Furosemide | 40 | 19 |
| Prednisone | Prednisone | 40 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 12 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | 12 |
| Celecoxib | Celecoxib | 29 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Nystatin | Nystatin | 28 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Acarbose | Acarbose | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | 11 |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Apidra Solostar | Insulin Glulisine | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $315.98 · 15 records | ABBVIE INC. | CONTRAVE, CREON, ELIQUIS, LINZESS, NP Thyroid 60, Ozempic, QSYMIA, Rybelsus, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error